Low expression levels of SAMHD1 protein as detected by immunohistochemistry were not associated with achievement of CR in two independent cohorts of AML patients of different risk groups in the present study, not even in the subgroup of patients that received HDAC as part of their induction therapy. Here, SAMHD1 is linked to acute myeloid leukemia.